|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 44.55 TWD | +1.25% |
|
+13.36% | -31.57% |
| 06-19 | Tanvex BioPharma, Inc. Appoints Val Chen as Corporate Governance Officer, Effective July 1, 2024 | CI |
| 06-19 | Tanvex BioPharma, Inc. Announces Change of Audit Committee Members | CI |
Tanvex BioPharma, Inc. reported earnings results for the first quarter ended March 31, 2024. For the first quarter, the company reported sales was TWD 3.36 million compared to TWD 30.14 million a year ago. Net loss was TWD 418.16 million compared to TWD 608.2 million a year ago.
Basic loss per share from continuing operations was TWD 3.12 compared to TWD 5.17 a year ago. Diluted loss per share from continuing operations was TWD 3.12 compared to TWD 5.17 a year ago.
| 1st Jan change | Capi. | |
|---|---|---|
| -31.57% | 221M | |
| +16.41% | 122B | |
| +19.56% | 115B | |
| +21.22% | 26.64B | |
| -23.60% | 19.91B | |
| -17.47% | 16.32B | |
| -45.95% | 15.52B | |
| -18.79% | 15.49B | |
| +62.33% | 14.83B | |
| +2.03% | 13.67B |
TANVEX BIOPHARMA, INC. 
